Spironolactone for heart failure with preserved ejection fraction

New England Journal of Medicine

Volumn 371, Issue 2, 2014, Pages 180-

  Kumar, Nilay ^a   Garg, Neetika ^b  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; SPIRONOLACTONE;

DISEASE ASSOCIATION; DRUG EFFECT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84903885438     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1405715     Document Type: Letter

References (4)

1. Fertin M, Dubois E, Belliard A, Amouyel P, Pinet F, Bauters C. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol 2012;110:277-83.
2. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-71.
3. Izumiya Y, Hanatani S, Kimura Y, et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014;30:338-44.
4. de Boer RA, Edelmann F, Cohen-Solal A, Mamas MA, Maisel A, Pieske B. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013;15:1095-101.